We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 109

CRS report focuses on pharmaceutical patent settlements
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

The Congressional Research Service (CRS) recently issued a report titled "Pharmaceutical Patent Settlements: Issues in Innovation and


New forum for patent disputes?
  • Shook Hardy & Bacon LLP
  • USA
  • March 24 2011

According to a news source, at least one major pharmaceutical company has filed a complaint before the International Trade Commission (ITC) seeking an exclusion order to block the importation of a generic version of one of its patented drugs


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • August 7 2014

The U.S. Patent & Trademark Office (USPTO) selects 19 law schools to join its Law School Clinic Certification Pilot Program. Four of the law schools


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • July 17 2014

The U.S. Food and Drug Administration issues guidance titled "Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal, Food


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The U.S. Food and Drug Administration (FDA) makes available Guidance for Industry and staff titled "Molecular Diagnostic Instruments with Combined


News Bytes
  • Shook Hardy & Bacon LLP
  • USA
  • February 13 2014

The U.S. Patent and Trademark Office requests comments by March 3, 2014, on the revision of a previously approved information collec- tion concerning


Australian court finds human gene mutation to be patentable
  • Shook Hardy & Bacon LLP
  • Australia, USA
  • September 11 2014

A full panel of the Federal Court of Australia has upheld its earlier ruling that an isolated but naturally occurring nucleic acid, BRCA1, can be


Argument on remand scheduled in Myriad Genetics
  • Shook Hardy & Bacon LLP
  • USA
  • May 17 2012

The Federal Circuit Court of Appeals has scheduled briefing and oral argument in Association for Molecular Pathology v. U.S. Patent and Trademark Office (Myriad Genetics), which the U.S. Supreme Court remanded for reconsideration in light of the Court’s ruling in Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012


NGOs request march-in rights for patented drug
  • Shook Hardy & Bacon LLP
  • USA
  • November 1 2012

Four non-governmental organizations (NGOs) have filed a petition with the National Institutes of Health (NIH) requesting that it grant march-in rights under the Bayh-Dole Act for a patented drug that they claim is “a federally funded invention that is much more expensive in the United States than in Canada, Europe or other high-income countries.”


CRS issues overview of IP issues for gene-related discoveries
  • Shook Hardy & Bacon LLP
  • USA
  • August 29 2013

The Congressional Research Service (CRS) recently released a report titled "Gene Patents: A Brief Overview of Intellectual Property Issues." The